CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) – Analysts at SVB Leerink dropped their Q2 2022 earnings per share estimates for CRISPR Therapeutics in a report issued on Monday, May 9th. SVB Leerink analyst R. Bienkowski now forecasts that the company will post earnings of ($2.22) per share for the quarter, down from their previous estimate of ($1.76). SVB Leerink has a “Outperform” rating and a $120.00 price target on the stock. SVB Leerink also issued estimates for CRISPR Therapeutics’ Q3 2022 earnings at ($2.21) EPS, Q4 2022 earnings at ($2.26) EPS, FY2022 earnings at ($9.16) EPS and FY2023 earnings at ($8.94) EPS.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last released its quarterly earnings results on Monday, May 9th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.94) by ($0.38). CRISPR Therapeutics had a return on equity of 12.77% and a net margin of 34.04%. The firm had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $2.45 million. During the same period in the prior year, the firm posted ($1.51) earnings per share. CRISPR Therapeutics’s revenue for the quarter was up 74.4% compared to the same quarter last year.
Shares of CRISPR Therapeutics stock opened at $52.23 on Thursday. The firm has a market capitalization of $4.05 billion, a P/E ratio of 14.52 and a beta of 2.05. The firm’s 50 day moving average is $59.37 and its two-hundred day moving average is $68.35. CRISPR Therapeutics has a 52 week low of $42.51 and a 52 week high of $169.76.
Hedge funds have recently added to or reduced their stakes in the stock. Capital Impact Advisors LLC purchased a new stake in shares of CRISPR Therapeutics during the 4th quarter worth $26,000. Elkhorn Partners Limited Partnership raised its position in shares of CRISPR Therapeutics by 180.0% during the 4th quarter. Elkhorn Partners Limited Partnership now owns 350 shares of the company’s stock valued at $27,000 after acquiring an additional 225 shares in the last quarter. Kistler Tiffany Companies LLC increased its position in CRISPR Therapeutics by 6,250.0% in the fourth quarter. Kistler Tiffany Companies LLC now owns 381 shares of the company’s stock worth $29,000 after buying an additional 375 shares during the period. CI Investments Inc. acquired a new position in shares of CRISPR Therapeutics during the third quarter valued at $30,000. Finally, IronBridge Private Wealth LLC bought a new position in CRISPR Therapeutics during the fourth quarter valued at about $30,000. Hedge funds and other institutional investors own 56.12% of the company’s stock.
About CRISPR Therapeutics (Get Rating)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.